PharVision Advisers’s iRadimed IRMD Stock Holding History

PharVision Advisers’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,608	Closed	-$257K	–	843
2025 Q3	$257K	Buy	+3,608	New	+$240K	0.14%	317

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's IRMD Position: Q4 2025 in Review

PharVision Advisers sold out of iRadimed (IRMD) in Q4 2025, closing a stake of 3,608 shares — an estimated $257K sold.

PharVision Advisers first reported a position in IRMD in Q3 2025 and held it in 1 quarter. The position peaked at $257K in Q3 2025. 217 funds tracked by Wall St. Rank hold IRMD as of Q4 2025.

PharVision Advisers reported no remaining iRadimed position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 3,608 iRadimed shares in Q4 2025, an estimated $257K.
PharVision Advisers first reported a position in iRadimed in Q3 2025 and held it in 1 quarter.
PharVision Advisers's iRadimed position peaked at $257K in Q3 2025.
217 funds tracked by Wall St. Rank held iRadimed as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.